维普期刊资源整合服务平台（V6.5）

36篇 您的检索式：作者名="Sikov"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer显示文摘	Sikov WM Perou CM Golsham M	2010	J Clin Oncol2010，28，15：	1
2	Primary systemic amyloidosis and persistent pleural effusions显示文摘	Schwarz D Jue C Sikov W	2009	Amyloid2009，16，4：	1
3	Splenosis presenting as occult gastrointestinal bleeding显示文摘	Sikov WM Schiffman FJ Weaver M	2000	Am J Hematol2000，65，1：	1
4	Testing of select workplacechemicals for teratogenic potential显示文摘	Hardin B D Bond G P Sikov M R	1981	Scand J Work Environ Health1981，7，4：	1
5	Impact of the addition ofcarboplatin and/or bevacizumab to neoadjuvant once- per- week paclitaxel followed by dose-dense doxorubicin and cyclophospha mide on pathologic complete response rates in stage 11 to ]]I triple- negative breast cancer:CALGB 40603 (Alliance)显示文摘	Sikov WM Berry DA Perou CM	2015	J Clin Onco12015，33，1：	1
6	Neoadjuvant Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Radiation for Rectal Cancer显示文摘	Tom Dipetrillo Victor Pricolo Jorge Lagares-Garcia Matt Vrees Adam Klipfel Tom Cataldo William Sikov Brendan McNulty Joshua Shipley Elliot Anderson Humera Khurshid Brigid Oconnor Nicklas B.E. Oldenburg Kathy Radie-Keane Syed Husain Howard Safran	2012	International Journal of Radiation Oncology Biology Physics2012，，1：	1
7	Neoadjuvant Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Radiation for Rectal Cancer显示文摘	Tom Dipetrillo Victor Pricolo Jorge Lagares-Garcia Matt Vrees Adam Klipfel Tom Cataldo William Sikov Brendan McNulty Joshua Shipley Elliot Anderson Humera Khurshid Brigid Oconnor Nicklas B.E. Oldenburg Kathy Radie-Keane Syed Husain Howard Safran	2012	International Journal of Radiation Oncology Biology Physics2012，，1：	1
8	Dual HER2-targeting without chemotherapy and estrogen deprivation in the neoadjnvant setting 显示文摘	Sikov WM	2014	Gland Surg2014，3，1：	1
9	Impact of Neoadjuvant Chemotherapy in Stage II-III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates:Surgical Results From CALGB 40603(Alliance)显示文摘	Golshan M Cirrincione CT Sikov WM	2015	Ann Surg2015，262，3：	1
10	Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week pacli- taxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage 1I to m triple-negative breast cancer: CALGB 40603 (Alliance) 显示文摘	Sikov WM Berry DA Pereu CM	2015	J Clin Oncol2015，33，1：	1
11	Impact of the addition of carbopladn and/or bevacizumab to neoadjuvant once-per-week pacfitaxel followed by dose-dense doxorubicin and cyclophospha- mide on pathologic complete response rates in stage Ⅱ to Ⅲ tri- ple-negative breast cancer: CALGB 40603 (Alliance)显示文摘	Sikov WM Berry DA Perou CM	2015	j Clin Oncol2015，33，1：	1
12	Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab:a Brown University Oncology Group study显示文摘	Sikov WM Dizon DS Strenger R		0，，：	1
13	Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophos- phamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)显示文摘	Sikov WM Berry DA Perou CM	2015	J Clin Oncol2015，33，1：	1
14	Relevance of p CR in breast cancer trials显示文摘	Sikov W M	2014	Oncology(Williston Park)2014，28，10：	1
15	Testing of select workplace chemicals for teratogenic potential显示文摘	Hardin BD Bond GP Sikov MR	1981	Scand J work Environ Health1981，7，4：	1
16	Frequent pathologic com- plete responses in aggressive stages Ⅱ to Ⅲ breast cancers with every - 4 - week carboplatin and weekly paclitaxel with or without trastuzumab:A Brown University Oncology Group Study 显示文摘	Sikov WM Dizon DS Strenger R	2009	J Chn Oneo12009，27，28：	1
17	Impact of neoadjuvantchemotherapy in stage II -ID triple negative breast cancer on eligibilityfor breast-conserving surgery and breast conservation rates : surgicalresults from CALGB 40603 (Alliance) 显示文摘	Golshan M Cirrincione CT Sikov WM	2015	Ann Surg2015，262，43：	1
18	Impact of the addi- tion of carboplatin (Cb) and/or bevacizumab (B) to neo- adjuvant weekly paclitaxel (P) followed by dose dense AC on pathologic complete response (pCR) rates in tri- ple-negative breast cancer (TNBC): CALGB 40603 (Al- liance) 显示文摘	Sikov W Berry D Perou C	2015	J Clin Oncol2015，33，1：	1
19	Impact of the ad- dition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxoru- bicin and cyclophosphamide on pathologic complete re- sponse rates in stage 11 to 111 triple-negative breast can- cer: CALGB 40603(Alliance)显示文摘	Sikov WM Berry DA Perou CM	2015	J Clin Oncol2015，33，1：	1
20	Impact of the addition ofcarboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to HI triple-negative breast cancer: CALGB 40603 (Alliance) 显示文摘	Sikov WM Berry DA Perou CM	2015	J Clin Oncol2015，33，1：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示